Dr Dana Shor

Dr Dana Shor is a Consultant in Clinical Oncology in Cambridge who specialises in the treatment of lung and upper gastrointestinal (oesophageal, gastric and small bowel) cancers and cancer of unknown primary (CUP). She provides expert, compassionate care across a full range of treatments, including systemic therapies (chemotherapy, immunotherapy and targeted therapy), conventional radiotherapy, and stereotactic ablative radiotherapy (SABR) for thoracic and upper GI malignancies.

Dr Shor completed a prestigious fellowship at the Odette Cancer Centre in Toronto, where she gained advanced expertise in SABR for lung, bone, and spine metastases, as well as stereotactic radiosurgery (SRS) for brain metastases.

In her current role at Cambridge University Hospital and Papworth Hospital, Dr Shor is part of a leading oncology team within the Department of Oncology. She serves as a principal investigator for several multicenter clinical trials, helping to advance future cancer care.

Dr Shor is committed to teaching and mentorship, having supported the British Oncology Network for Undergraduate Society. She is a trainee editor for the Clinical Oncology journal and contributes regularly to OncoFlash publications, providing updates on the latest radiotherapy research.

Clinical interests:

-All lung malignancies (early to metastasis stage)

-Malignant mesothelioma 

-Upper GI malignancy (oesophageal, gastric, small bowel cancers)

-Tumours of unknown primary (CUP)

- Chemotherapy 

-Immunotherapy 

-Targeted therapy/molecular driver systemic therapy 

-Conventional radiotherapy 

-Stereotactic ablative radiotherapy (SABR) for lung, spine and bone metastases

-Radiotherapy for brain metastases and post op (PORT) brain cavity radiotherapy 

-Pallitive radiotherapy